BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 34725206)

  • 21. One-stop molecular classification of endometrial carcinoma using comprehensive next-generation sequencing.
    Li Y; Chen R; Yuan M; Wang D; Fu C; Chen R; Lei C; Zhou Q
    Int J Cancer; 2022 Dec; 151(11):1969-1977. PubMed ID: 36036365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis.
    Koul A; Willén R; Bendahl PO; Nilbert M; Borg A
    Cancer; 2002 May; 94(9):2369-79. PubMed ID: 12015762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.
    Madore J; Ren F; Filali-Mouhim A; Sanchez L; Köbel M; Tonin PN; Huntsman D; Provencher DM; Mes-Masson AM
    J Pathol; 2010 Feb; 220(3):392-400. PubMed ID: 19967725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TP53 mutations in endometrial cancers: relation to PTEN gene defects.
    Janiec-Jankowska A; Konopka B; Goluda C; Najmoła U
    Int J Gynecol Cancer; 2010 Feb; 20(2):196-202. PubMed ID: 20169661
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Classification of Endometrial Carcinoma: New Perspectives Beyond Morphology.
    Akhtar M; Al Hyassat S; Elaiwy O; Rashid S; Al-Nabet ADMH
    Adv Anat Pathol; 2019 Nov; 26(6):421-427. PubMed ID: 31567131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
    Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
    Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathology of Endometrial Carcinoma.
    Lax SF
    Adv Exp Med Biol; 2017; 943():75-96. PubMed ID: 27910065
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differences in patterns of TP53 and KRAS2 mutations in a large series of endometrial carcinomas with or without microsatellite instability.
    Swisher EM; Peiffer-Schneider S; Mutch DG; Herzog TJ; Rader JS; Elbendary A; Goodfellow PJ
    Cancer; 1999 Jan; 85(1):119-26. PubMed ID: 9921983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypoxia contributes to development of recurrent endometrial carcinoma.
    Pijnenborg JM; Wijnakker M; Hagelstein J; Delvoux B; Groothuis PG
    Int J Gynecol Cancer; 2007; 17(4):897-904. PubMed ID: 17359291
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary.
    Sato N; Tsunoda H; Nishida M; Morishita Y; Takimoto Y; Kubo T; Noguchi M
    Cancer Res; 2000 Dec; 60(24):7052-6. PubMed ID: 11156411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Massively parallel sequencing identifies recurrent mutations in TP53 in thymic carcinoma associated with poor prognosis.
    Moreira AL; Won HH; McMillan R; Huang J; Riely GJ; Ladanyi M; Berger MF
    J Thorac Oncol; 2015 Feb; 10(2):373-80. PubMed ID: 25299233
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.
    Garcia-Dios DA; Lambrechts D; Coenegrachts L; Vandenput I; Capoen A; Webb PM; Ferguson K; ; Akslen LA; Claes B; Vergote I; Moerman P; Van Robays J; Marcickiewicz J; Salvesen HB; Spurdle AB; Amant F
    Gynecol Oncol; 2013 Feb; 128(2):327-34. PubMed ID: 23219661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutation spectrum of POLE and POLD1 mutations in South East Asian women presenting with grade 3 endometrioid endometrial carcinomas.
    Wong A; Kuick CH; Wong WL; Tham JM; Mansor S; Loh E; Jain S; Vikas NN; Tan SH; Chan SH; Li ST; Chew SH; Hong W; Ngeow J
    Gynecol Oncol; 2016 Apr; 141(1):113-20. PubMed ID: 26748215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular profiling and molecular classification of endometrioid ovarian carcinomas.
    Cybulska P; Paula ADC; Tseng J; Leitao MM; Bashashati A; Huntsman DG; Nazeran TM; Aghajanian C; Abu-Rustum NR; DeLair DF; Shah SP; Weigelt B
    Gynecol Oncol; 2019 Sep; 154(3):516-523. PubMed ID: 31340883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TP53 protein expression analysis by luminometric immunoassay in comparison with gene mutation status and prognostic factors in early stage endometrial cancer.
    Koul A; Bendahl PO; Borg A; Fernö M; Lidebring MF; Högberg T; Einarsson EL; Ridderheim M; Willén R
    Int J Gynecol Cancer; 2002; 12(4):362-71. PubMed ID: 12144684
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular approaches for classifying endometrial carcinoma.
    Piulats JM; Guerra E; Gil-Martín M; Roman-Canal B; Gatius S; Sanz-Pamplona R; Velasco A; Vidal A; Matias-Guiu X
    Gynecol Oncol; 2017 Apr; 145(1):200-207. PubMed ID: 28040204
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The NRF2 transcriptional target NQO1 has low mRNA levels in TP53-mutated endometrial carcinomas.
    Beinse G; Just PA; Rance B; Izac B; Letourneur F; Saidu NEB; Chouzenoux S; Nicco C; Goldwasser F; Pasmant E; Batteux F; Borghese B; Alexandre J; Leroy K
    PLoS One; 2019; 14(3):e0214416. PubMed ID: 30908539
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clonal evolution in paired endometrial intraepithelial neoplasia/atypical hyperplasia and endometrioid adenocarcinoma.
    Russo M; Broach J; Sheldon K; Houser KR; Liu DJ; Kesterson J; Phaeton R; Hossler C; Hempel N; Baker M; Newell JM; Zaino R; Warrick JI
    Hum Pathol; 2017 Sep; 67():69-77. PubMed ID: 28712776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.
    Kuhn E; Wu RC; Guan B; Wu G; Zhang J; Wang Y; Song L; Yuan X; Wei L; Roden RB; Kuo KT; Nakayama K; Clarke B; Shaw P; Olvera N; Kurman RJ; Levine DA; Wang TL; Shih IeM
    J Natl Cancer Inst; 2012 Oct; 104(19):1503-13. PubMed ID: 22923510
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment.
    Peiró G; Peiró FM; Ortiz-Martínez F; Planelles M; Sánchez-Tejada L; Alenda C; Ceballos S; Sánchez-Payá J; Laforga JB
    Hum Pathol; 2013 Feb; 44(2):218-25. PubMed ID: 22955108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.